ALD

MetaVia Reports 68% Liver Fat Reduction With DA-1726

Cambridge, Massachusetts, USA, November 5, 2026 MetaVia Inc. has announced promising interim clinical results demonstrating a statistically significant 68%...

By cGxPwire Editor
November 7, 2026

Bio-Pharma

Altimmune Reports Positive Phase 2 RECLAIM Results for Pemvidutide in Alcohol Use Disorder

GAITHERSBURG, Md., July 28, 2026 Altimmune, Inc. announced positive topline results from its Phase 2 RECLAIM clinical trial evaluating...

By cGxPwire Editor
July 29, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

ALD

MetaVia Reports 68% Liver Fat Reduction With DA-1726

Altimmune Reports Positive Phase 2 RECLAIM Results for Pemvidutide in Alcohol Use Disorder